These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 39107284)

  • 1. Reprogramming the tumor immune microenvironment using engineered dual-drug loaded Salmonella.
    Nguyen DH; You SH; Ngo HT; Van Nguyen K; Tran KV; Chu TH; Kim SY; Ha SJ; Hong Y; Min JJ
    Nat Commun; 2024 Aug; 15(1):6680. PubMed ID: 39107284
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Two-step enhanced cancer immunotherapy with engineered
    Zheng JH; Nguyen VH; Jiang SN; Park SH; Tan W; Hong SH; Shin MG; Chung IJ; Hong Y; Bom HS; Choy HE; Lee SE; Rhee JH; Min JJ
    Sci Transl Med; 2017 Feb; 9(376):. PubMed ID: 28179508
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synergistic cancer immunotherapy utilizing programmed Salmonella typhimurium secreting heterologous flagellin B conjugated to interleukin-15 proteins.
    Zhang Y; Tan W; Sultonova RD; Nguyen DH; Zheng JH; You SH; Rhee JH; Kim SY; Khim K; Hong Y; Min JJ
    Biomaterials; 2023 Jul; 298():122135. PubMed ID: 37148758
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumor Microenvironment-Regulating Immunosenescence-Independent Nanostimulant Synergizing with Near-Infrared Light Irradiation for Antitumor Immunity.
    Uthaman S; Pillarisetti S; Hwang HS; Mathew AP; Huh KM; Rhee JH; Park IK
    ACS Appl Mater Interfaces; 2021 Feb; 13(4):4844-4852. PubMed ID: 33486952
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A spontaneous multifunctional hydrogel vaccine amplifies the innate immune response to launch a powerful antitumor adaptive immune response.
    Liang X; Li L; Li X; He T; Gong S; Zhu S; Zhang M; Wu Q; Gong C
    Theranostics; 2021; 11(14):6936-6949. PubMed ID: 34093863
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cancer-associated fibroblast-targeted strategy enhances antitumor immune responses in dendritic cell-based vaccine.
    Ohshio Y; Teramoto K; Hanaoka J; Tezuka N; Itoh Y; Asai T; Daigo Y; Ogasawara K
    Cancer Sci; 2015 Feb; 106(2):134-42. PubMed ID: 25483888
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Modulating the innate immune activity in murine tumor microenvironment by a combination of inducer molecules attached to microparticles.
    Shahar E; Gorodetsky R; Aizenshtein E; Lalush L; Pitcovski J
    Cancer Immunol Immunother; 2015 Sep; 64(9):1137-49. PubMed ID: 26031575
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In situ formed reactive oxygen species-responsive dipyridamole prodrug hydrogel: Spatiotemporal drug delivery for chemoimmunotherapy.
    Xiao B; Shi X; Xu X; Liu J; Pan Y; Xu H; Sun W; Slater NKH; Patra HK; Gao J; Shen Y; Tang J
    J Control Release; 2024 Nov; 375():454-466. PubMed ID: 39216598
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nanocatalytic Innate Immunity Activation by Mitochondrial DNA Oxidative Damage for Tumor-Specific Therapy.
    Jiang H; Guo Y; Wei C; Hu P; Shi J
    Adv Mater; 2021 May; 33(20):e2008065. PubMed ID: 33797131
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting of pancreatic cancer cells and stromal cells using engineered oncolytic Salmonella typhimurium.
    Tan W; Duong MT; Zuo C; Qin Y; Zhang Y; Guo Y; Hong Y; Zheng JH; Min JJ
    Mol Ther; 2022 Feb; 30(2):662-671. PubMed ID: 34400328
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dual-Engineered Macrophage-Microbe Encapsulation for Metastasis Immunotherapy.
    Wu L; Qiao L; Zhang S; Qiu J; Du Z; Sun Y; Chang X; Li L; Li C; Qiao X; Yin X; Hua Z
    Adv Mater; 2024 Sep; 36(36):e2406140. PubMed ID: 39023382
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MDM2 inhibitor APG-115 synergizes with PD-1 blockade through enhancing antitumor immunity in the tumor microenvironment.
    Fang DD; Tang Q; Kong Y; Wang Q; Gu J; Fang X; Zou P; Rong T; Wang J; Yang D; Zhai Y
    J Immunother Cancer; 2019 Nov; 7(1):327. PubMed ID: 31779710
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intratumoral CpG-B Promotes Antitumoral Neutrophil, cDC, and T-cell Cooperation without Reprograming Tolerogenic pDC.
    Humbert M; Guery L; Brighouse D; Lemeille S; Hugues S
    Cancer Res; 2018 Jun; 78(12):3280-3292. PubMed ID: 29588348
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ALX148 blocks CD47 and enhances innate and adaptive antitumor immunity with a favorable safety profile.
    Kauder SE; Kuo TC; Harrabi O; Chen A; Sangalang E; Doyle L; Rocha SS; Bollini S; Han B; Sim J; Pons J; Wan HI
    PLoS One; 2018; 13(8):e0201832. PubMed ID: 30133535
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chloroquine modulates antitumor immune response by resetting tumor-associated macrophages toward M1 phenotype.
    Chen D; Xie J; Fiskesund R; Dong W; Liang X; Lv J; Jin X; Liu J; Mo S; Zhang T; Cheng F; Zhou Y; Zhang H; Tang K; Ma J; Liu Y; Huang B
    Nat Commun; 2018 Feb; 9(1):873. PubMed ID: 29491374
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeted cancer immunotherapy with genetically engineered oncolytic Salmonella typhimurium.
    Guo Y; Chen Y; Liu X; Min JJ; Tan W; Zheng JH
    Cancer Lett; 2020 Jan; 469():102-110. PubMed ID: 31666180
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multifunctional silica nanocomposites prime tumoricidal immunity for efficient cancer immunotherapy.
    Yang L; Li F; Cao Y; Liu Q; Jing G; Niu J; Sun F; Qian Y; Wang S; Li A
    J Nanobiotechnology; 2021 Oct; 19(1):328. PubMed ID: 34663354
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Boosting Potential of Bacteria in Cancer Immunotherapy.
    Binder DC; Wainwright DA
    Trends Mol Med; 2017 Jul; 23(7):580-582. PubMed ID: 28583420
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting CAMKII to reprogram tumor-associated macrophages and inhibit tumor cells for cancer immunotherapy with an injectable hybrid peptide hydrogel.
    Dai X; Meng J; Deng S; Zhang L; Wan C; Lu L; Huang J; Hu Y; Zhang Z; Li Y; Lovell JF; Wu G; Yang K; Jin H
    Theranostics; 2020; 10(7):3049-3063. PubMed ID: 32194854
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Modulation of the tumor microenvironment by intratumoral administration of IMO-2125, a novel TLR9 agonist, for cancer immunotherapy.
    Wang D; Jiang W; Zhu F; Mao X; Agrawal S
    Int J Oncol; 2018 Sep; 53(3):1193-1203. PubMed ID: 29956749
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.